User Notice: The old Support number is no longer in use. To reach Support please call +44 (0) 203 8794 460

Circassia Pharmaceuticals Dividends - CIR

Circassia Pharmaceuticals Dividends - CIR

Best deals to access real time data!
Silver
Monthly Subscription
for only
£17.37
Level 2 Basic
Monthly Subscription
for only
£62.08
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Circassia Pharmaceuticals CIR London Ordinary Share GB00BJVD3B28 ORD 0.08P
  Price Change Price Change % Stock Price High Price Low Price Open Price Close Price Last Trade
  -0.15 -0.82% 18.25 18.50 18.20 18.50 18.40 10:44:52
more quote information »
Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Circassia Pharmaceuticals CIR Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount
01/01/1970FinalGBP031/12/200431/12/200501/01/197001/01/197001/01/19700
01/01/1970FinalGBP031/12/200331/12/200401/01/197001/01/197001/01/19700
01/01/1970FinalGBP031/12/200231/12/200301/01/197001/01/197001/01/19700
uk top

Top Dividend Posts

DateSubject
17/6/2019
19:06
researchanalyst1: Rathean, you're spot on. Beginning on May 06 2019 – when the share price was 31.05p – Circassia has suffered a rare capitulation that is wholly disconnected to its fundamentals. Selling cascaded to extremes as stop losses were sequentially triggered, battering this junior pharma to exceedingly low levels. While very challenging psychologically, capitulations are super-bullish. They rapidly exhaust all near-term selling potential, leaving stocks wildly oversold and undervalued which, in turn, ushers in major new uplegs. The word capitulation, after all, means ‘the act of surrendering or giving up’. That’s exactly what’s happened in this extraordinary selling event; investors simply bolted for the exits. Exceptionally-bearish investor sentiment hit the company following grossly exaggerated rumours of a gargantuan fire sale by Woodford which proved to be wholly unfounded. In the end, WIM only sold 4% of its 28.03% stake to stand at 24.47% on June 06 2019 whilst Invesco and St James hoovered-up the dirt cheap shares albeit with a miniscule reduction from Invesco thereafter. And since then, on June 10 2019, Woodford has come out to re-assure investors that his fire sale is well and truly done after raising £500m to fulfil outstanding redemptions. Http://www.morningstar.co.uk/uk/news/AN_1560170000672276500/woodford-raises-gbp500-million-from-flurry-of-london-share-sales-%28alliss%29.aspx Thus, my point is, the stock is now grossly oversold on the following grounds: Circassia’s market cap is currently £60.9m (16.25p). Less cash and cash equivalents of £40.34m means the market is valuing Duaklir®, Tudorza®, NIOX®, and AirNOvent at £20.6m! Seriously? Does anyone out there really believe that Duaklir®, Tudorza®, NIOX®, and AirNOvent are collectively worth £20.6m? For crying out loud, the company’s audited value of its net assets, as stated in its May 01 2019 final results, stood at £125.9 million! Thus, it is vacuous nonsense to suggest that Duaklir®, Tudorza®, NIOX®, and AirNOvent are collectively worth £20m when their 2019 forecasted revenues are in excess of £74m! Yes, Circassia is on track to materially increase NIOX® revenues in China following the implementation of direct sales in the country, Tudorza® revenues following the exercise of the option at the end of 2018, and Duaklir® revenues following the product's approval by the FDA at the end of March. Thus, as far as gross undervaluations go, Circassia Pharma is off the scale. That being said, the negative sentiment appears to have finally petered out with the share price hitting an all-time low of 16.10p in the last half hour of trading, following a flurry of stop losses, before closing up at 16.25p (the true closing price not the UT price). To this end, disregard the ‘noise’ and take cue from the 250k buy that went through at the ridiculous price of 16.30p. I call it smart money. .
06/6/2019
18:12
the abbot: Lol there you go again a late sell as the UT to push the share price negative at the end of the day.
06/6/2019
09:25
pre: so 2 issues here which create uncertainty and may affect share price: 1. woodfords holding of 28% by far the largest...if he sells on the market this could create significant volatility, or will he find another home? 2. Final deferred payment of $100 million is due by 30 June 2019 to Astrazeneca - how are CIR going to raise this? more dilution for shareholders??
04/6/2019
16:04
aspringo: Not that the attached is overly helpful but asked some question of Circassia and the reply is below. Understand its a standard response but thought they should know we're not happy..The Company is also disappointed with the share price decline, which has occurred despite a number of positive developments in the business announced in recent months.  In terms of the market, both the sector and a number of UK small / mid-cap companies have experienced significant turbulence, which is also likely impacted by wider global concerns.  In terms of managing the business, we announced full year results at the beginning of May, where the Company outlined recent progress and we remain focused on driving the business forward.   Thanks again for your note. Kind regards
04/6/2019
08:31
ltinvestor: Outside factors may have provided us with an extremely undervalued business.Normally a share price fall is a reflection on how badly a business is trading which does not appear to be the case here.I suspect the companies brokers are looking to place the Woodford holding and may even have started the process with over 30m shares traded yesterday...
03/6/2019
13:34
the abbot: Certainly if nothing else the CEO is guilty of gross incompetence. They sit back in their ivory tower thinking they ,'deserve' their renumeration due to the level of other CEO salaries, however not all ceo's are made of the same stuff and some just don't come up to the mark. Steve Harris has shown himself to be failing, he has shown he cannot control his board from immediately selling vested options, thus sending a poor message to the market, he has shown that he controls, based on share price performance, a failing business and he has shown incompetence in being able to direct his brokers to protect the share price from shorters. He has made no attempt to rectify the position by either director purchases or buybacks. And has failed in his marketing to produce anything worthy to sell the business such as analysts notes or for example some Edison research. In fact mostly he has only used proactive investors in which the audio is rubbish and he just comes across as smug. In all ways possible, if I had a hand in this I would be recommending all shareholders to vote against his approval at the AGM and seek alternative competent management, with an IR department that does not place themselves above the shareholders. But acts to support requests in which to aid and further the business.
02/6/2019
22:28
maybesum: Turvat it depends on your timeframe....the company has very good prospects, yes the share price has dropped, but then so has the whole market. How deep are you in here if I may ask...or are you a holder at all? What about the two 27thousand pound buys just before close on Friday?
11/5/2019
15:58
turvart: Do CIr have any exposure to UK sales?
02/5/2019
10:43
badger60: the abbotYep..... unfortunately these days many promising small caps are very poorly marketed and/or become the object of manipulation by mms.....so nearly everybody (understandably) becomes a trader, and I'm not too good at that.The big money for me is (choosing the right stock) made by being patient. On balance I have done well over the years, but also taken a few chunky hits along the way. Hemogenyx imo is potentially a serious multibagger, but it has been unloved, overlooked and very badly handled by the market since it came in October 2017, and like CIR much of the the embedded value is in no way reflected in the share price or market cap. ......but that's what no pain, no gain is all about.Good luck here....ttfn.
01/5/2019
18:42
gersemi: 6 hours ago Circassia slashes net cash outflow By Mark Robinson Drug developers require a steady stream of positive clinical updates to underpin market valuations. Circassia Pharmaceuticals (CIE) provided shareholders with precisely that a month ahead of these full-year figures when it revealed that US regulators had given the green light for two of its chronic obstructive pulmonary disease (COPD) treatments. It is too early to say whether the news has arrested the share price decline of the previous 12-months, but given that very few UK-sponsored drugs have been approved in the US in the past few years, so the news - particularly in relation to the Duaklir drug - would not have gone unnoticed amongst the sector heavyweights. The drugs are complementary in that patients using its existing COPD treatment Tudorza (which got the go-ahead for the inclusion of new clinical data on its label) can move on to Duaklir if their condition deteriorates without needing to change their inhaler device. Bloomberg consensus gives revenues of £64.5m for the December 2019 year-end, with an accompanying adjusted earnings loss of 7.6p a share, before £84.8m and a 5.2p loss in the following year. CIRCASSIA PHARMACEUTICALS (CIR) ORD PRICE: 32p MARKET VALUE: £ 120m TOUCH: 31.2-32p 12-MONTH HIGH: 98p LOW: 25p DIVIDEND YIELD: NIL PE RATIO: NA NET ASSET VALUE: 34p* NET CASH: £40.7m Year to 31 Dec Turnover (£m) Pre-tax profit (£m) Earnings per share (p) Dividend per share (p) 2014 nil -44.0 -21 nil 2015 10.8 -62.8 -20 nil 2016 23.1 -38.8 -48 nil 2017 (restated) 46.3 -74.2 -19 nil 2018 48.3 -55.8 -14 nil % change +4 - - - Ex-div: - Payment: - *Includes intangible assets of £231m, or 61.5p a share. IC View Duaklir was initially approved in the European Union five years ago, but the US launch in the second half of 2019 is highly significant given the potential up-scale. With a new revenue stream in prospect, 2018 may come to be seen as a watershed for the company. Though the net cash-outflow fell by two-thirds to £18.8m, the continued backing by AstraZeneca (AZN), which boosted its holding to 19.9 per cent midway through last year, has been crucial. However, given the lowly free-float, shareholders may struggle to buy into the US growth story. Hold. Last IC view: Hold, 34p, 01 Apr 2019 end
Your Recent History
LSE
CIR
Circassia ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190716 10:30:52